Downstream effectors of oncogenic ras in multiple myeloma cells. [electronic resource]
Producer: 20030618Description: 3126-35 p. digitalISSN:- 0006-4971
- Alkyl and Aryl Transferases -- antagonists & inhibitors
- Cell Cycle
- Chromones -- pharmacology
- DNA-Binding Proteins -- metabolism
- Enzyme Inhibitors -- pharmacology
- Farnesyltranstransferase
- Flavonoids -- pharmacology
- Genes, ras
- I-kappa B Proteins -- genetics
- Interleukin-6 -- physiology
- MAP Kinase Signaling System -- drug effects
- Mitogen-Activated Protein Kinase 1 -- physiology
- Mitogen-Activated Protein Kinase 3
- Mitogen-Activated Protein Kinases -- physiology
- Morpholines -- pharmacology
- Multiple Myeloma -- genetics
- NF-kappa B -- physiology
- Neoplasm Proteins -- antagonists & inhibitors
- Oncogene Protein p21(ras) -- physiology
- Phosphatidylinositol 3-Kinases -- physiology
- Phosphoinositide-3 Kinase Inhibitors
- Phosphorylation -- drug effects
- Protein Kinase Inhibitors
- Protein Kinases -- physiology
- Protein Processing, Post-Translational -- drug effects
- Protein Serine-Threonine Kinases
- Proto-Oncogene Proteins -- antagonists & inhibitors
- Proto-Oncogene Proteins c-akt
- Recombinant Fusion Proteins -- physiology
- Ribosomal Protein S6 Kinases, 70-kDa -- physiology
- STAT3 Transcription Factor
- Signal Transduction -- drug effects
- Sirolimus -- pharmacology
- TOR Serine-Threonine Kinases
- Trans-Activators -- metabolism
- Transfection
- Tumor Cells, Cultured -- drug effects
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.